Evaluation of IGM-6268 in Healthy Volunteers

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2022
This is a Phase 1, multi-center, randomized, double-blinded, placebo-controlled single (SAD) and multiple ascending (MAD) ascending dose study to assess the safety, tolerability, and pharmacokinetics (PK) of IGM-6268 administered intranasally and intraorally in healthy volunteers. IGM-6268 or placebo will be administered by intranasal + intraoral spray using a Teleflex Mucosal Atomization Device Nasal™ Intranasal Mucosal Atomization Device once (SAD), or once or twice each day for 5 days (MAD).
Epistemonikos ID: 7f7b80dd84c69847edb7b9b90ffe73893a10493c
First added on: Oct 02, 2023